Cited by 345Alzheimer's disease research and treatmentsSirtuins and Resveratrol in MedicineNeuroinflammation and Neurodegeneration Mechanisms

Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models

Open access
Gong, Bing, Pan, Yong, Vempati, Prashant, Zhao, Wei, Knable, Lindsay, Ho, Lap, Wang, Jun, Sastre, Magdalena +3 more·2013·Neurobiology of Aging

Abstract

Nicotinamide adenine dinucleotide (NAD)(+), a coenzyme involved in redox activities in the mitochondrial electron transport chain, has been identified as a key regulator of the lifespan-extending effects, and the activation of NAD(+) expression has been linked with a decrease in beta-amyloid (Aβ) toxicity in Alzheimer's disease (AD). Nicotinamide riboside (NR) is a NAD(+) precursor, it promotes peroxisome proliferator-activated receptor-γ coactivator 1 (PGC)-1α expression in the brain. Evidence has shown that PGC-1α is a crucial regulator of Aβ generation because it affects β-secretase (BACE1) degradation. In this study we tested the hypothesis that NR treatment in an AD mouse model could attenuate Aβ toxicity through the activation of PGC-1α-mediated BACE1 degradation. Using the Tg2576 AD mouse model, using in vivo behavioral analyses, biochemistry assays, small hairpin RNA (shRNA) gene silencing and electrophysiological recording, we found (1) dietary treatment of Tg2576 mice with 250 mg/kg/day of NR for 3 months significantly attenuates cognitive deterioration in Tg2576 mice and coincides with an increase in the steady-state levels of NAD(+) in the cerebral cortex; (2) application of NR to hippocampal slices (10 μM) for 4 hours abolishes the deficits in long-term potentiation recorded in the CA1 region of Tg2576 mice; (3) NR treatment promotes PGC-1α expression in the brain coinciding with enhanced degradation of BACE1 and the reduction of Aβ production in Tg2576 mice. Further in vitro studies confirmed that BACE1 protein content is decreased by NR treatment in primary neuronal cultures derived from Tg2576 embryos, in which BACE1 degradation was prevented by PGC-1α-shRNA gene silencing; and (4) NR treatment and PGC-1α overexpression enhance BACE1 ubiquitination and proteasomal degradation. Our studies suggest that dietary treatment with NR might benefit AD cognitive function and synaptic plasticity, in part by promoting PGC-1α-mediated BACE1 ubiquitination and degradation, thus preventing Aβ production in the brain.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neurobiolaging.2012.12.005

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • NR protects cognitive function, synaptic plasticity, learning, memory, and motor function in Alzheimer disease models.

    “NR demonstrated protective effects on cognitive function, synaptic plasticity, learning, memory, and motor function in Alzheimer’s disease models [24, 27].”

    From NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health (2023) · cites this paper as [27]

    Results §3.1 reports improved object-recognition performance in NR-treated Tg2576 Alzheimer’s-model mice, supporting the cognitive, learning and memory aspects. Results §3.3 reports improved hippocampal long-term potentiation, supporting synaptic plasticity. The paper does not report a motor-function outcome, so it does not support that part of the claim. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • NR reduced beta-amyloid levels and increased the chance of recognizing a novel object by 20% in NR-treated Tg2576 mice.

    “It reduced the beta-amyloid levels, increasing the chance of recognizing a novel object by 20% in NR-treated Tg2576 mice [27].”
  • NAD+ augmentation via nicotinamide riboside supplementation induced the ubiquitin-proteasome system in both the hippocampus and cortex of Tg2576 Alzheimer's disease mice and restored the mitochondrial unfolded protein response in APPswe/PSEN1dE9 AD mice.

    “NAD+ augmentation via NR supplementation induced UPS in both the hippocampus and cortex of Tg2576 AD mice (Gong et al., 2013) and restored UPRmt in APPswe/PSEN1dE9 AD mice.”

    From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Gong et al., 2013

  • NAD+ depletion is reported in several models of accelerated ageing that exhibit neurodegeneration, as well as in neurodegenerative diseases including Alzheimer disease, Parkinson disease and amyotrophic lateral sclerosis.

    “NAD+ depletion is reported in several models of accelerated ageing which exhibit neurodegeneration33,134,135, as well as in neuro-degenerative diseases, including Alzheimer disease136, Parkinson disease137,138 and amyotrophic lateral sclerosis (ALS)139.”
  • NAD+ precursors NR and NMN improve neuronal cell health, memory and cognitive function in rat and mouse models of Alzheimer disease, and show neuroprotective properties in Drosophila models of Parkinson disease and mouse models of ALS.

    “the NAD+ precursors NR and NMN improve neuronal cell health, memory and cognitive function in rat and mouse models of Alzheimer disease136,161,175–180, and also showed neuroprotective properties in Drosophila melanogaster models of Parkinson disease181,182 and in mouse models of ALS139.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Gong, B., Pan, Y., Vempati, P., Zhao, W., Knable, L., Ho, L., Wang, J., Sastre, M., Ono, K., Sauve, A. A., & Pasinetti, G. M.
Affiliations
  • Icahn School of Medicine at Mount Sinai (US)
  • Imperial College London (GB)
  • Weill Cornell Medicine (US)
  • James J. Peters VA Medical Center (US)
Corresponding author
Pasinetti, Giulio M.
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
2013-06
Volume
34
Issue
6
Pages
1581-1588
ISSN
0197-4580 (ISSN-L)
OpenAlex
W2166956025
Cited by
345
References
34
Citations by year
2026: 18 · 2025: 22 · 2024: 28 · 2023: 36 · 2022: 33 · 2021: 40 · 2020: 32 · 2019: 32 · 2018: 27 · 2017: 27 · 2016: 18 · 2015: 13 · 2014: 11 · 2013: 6
FWCI
11.11
Type
journal article
Language
en
Open access
Locations
  • Neurobiology of Aging (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Veterans Administration by the US National Institutes of Health
  • Alzheimer's Association (IIRG-08-89354)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
nicotinamide riboside, Alzheimer's disease, PGC-1α, amyloid-beta, NAD+, Tg2576 mice, cognitive impairment, long-term potentiation, synaptic plasticity, ubiquitination, proteasomal degradation, mitochondrial gene expression, hippocampus
MeSH terms
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Alzheimer Disease, Animals, Cells, Cultured, Cognition Disorders, Disease Models, Animal, Gene Expression Regulation, Mice, Inbred C57BL, Mice, Transgenic, Mitochondria, Niacinamide, Organ Culture Techniques, Pyridinium Compounds, Transcription Factors, Up-Regulation, Aspartic Acid Endopeptidases, Mice, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review